Although we detected substantial expression of PD-L1 in a significant fraction of non-T-cell host immune cells and of PD-1 in host T cells, which seemed to correlate with tumor mutational burden (TMB), we did not observe pronounced anti-tumor effects for the treatment with PD-1-blocking antibodies. The gene discussed is PDCD1; the disease is neoplasm.